UHPLC-QTOF MS screening of pharmaceuticals and their metabolitesin treated wastewater samples from Athens
Impacte
Scholar |
Altres documents de l'autoria: Ibáñez, Maria; Borova, V.; Boix Sales, Clara; Aalizadeh, Reza; Bade, Richard; Thomaidis, Nikolaos; Hernandez, Felix
Metadades
Mostra el registre complet de l'elementcomunitat-uji-handle:10234/9
comunitat-uji-handle2:10234/33596
comunitat-uji-handle3:10234/33597
comunitat-uji-handle4:
INVESTIGACIONAquest recurs és restringit
http://dx.doi.org/10.1016/j.jhazmat.2016.03.078 |
Metadades
Títol
UHPLC-QTOF MS screening of pharmaceuticals and their metabolitesin treated wastewater samples from AthensAutoria
Data de publicació
2017-02Editor
ElsevierCita bibliogràfica
IBÁÑEZ, M., et al. UHPLC-QTOF MS screening of pharmaceuticals and their metabolites in treated wastewater samples from Athens. Journal of hazardous materials, 2017, vol. 323, p. 26-35.Tipus de document
info:eu-repo/semantics/articleVersió de l'editorial
http://www.sciencedirect.com/science/article/pii/S0304389416303028Paraules clau / Matèries
Resum
After consumption, pharmaceuticals are excreted as parent compounds and/or metabolites in urine and faeces. Some are not completely removed during wastewater treatments, forcing sewage treatment plants (STPs) to apply ... [+]
After consumption, pharmaceuticals are excreted as parent compounds and/or metabolites in urine and faeces. Some are not completely removed during wastewater treatments, forcing sewage treatment plants (STPs) to apply alternative technologies to guarantee quality of treated water. To monitor the removal efficiency of STPs, not only unchanged compounds and metabolites have to be taken into account, but also formation of possible transformation products (TPs). In this work, QTOF MS has been used for screening metabolites/TPs of pharmaceuticals in effluent wastewater from Athens. A customised database was built with the exact masses of metabolites reported in literature for the parent drugs found in an initial screening. Additionally, TPs identified in previous degradation experiments performed at our laboratory were included. Up to 34 metabolites/TPs were detected for omeprazole, venlafaxine, clindamycin, clarithromycin, clopidogrel or dipyrone, among others. Seven corresponded to TPs whose reference standards were available at our lab, seven were TPs previously identified in laboratory degradation experiments, eight were TPs tentatively identified by QTOF MS without reference standards, and twelve TPs were discovered after using the common fragmentation pathway approach. Tentative identification of TPs was supported by prediction of their chromatographic retention time based on the use of advanced chemometric QSRR models. [-]
Publicat a
Journal of hazardous materials, Volume 323, Part A, February 2017Drets d'accés
© 2016 Elsevier B.V. All rights reserved.
http://rightsstatements.org/vocab/InC/1.0/
info:eu-repo/semantics/restrictedAccess
http://rightsstatements.org/vocab/InC/1.0/
info:eu-repo/semantics/restrictedAccess
Apareix a les col.leccions
- IUPA_Articles [310]